EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients

Mary Mathias, Marina Abashidze, Aby Abraham, Mark J Belletrutti, Manuel Carcao iD, Hervé Chambost, Anthony K C Chan, Leonid Dubey, Jonathan Ducore, Thierry Lambert, Natalya Kavardakova, Sunil Lohade und 3 weitere

Haemophilia · 2023

DOI: 10.1111/hae.14796 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Haemophilia, 2023. Verfasst von Mary Mathias und 14 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, NIHR GOSH BRC, London, UK. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Octapharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The NuProtect study reported data on the immunogenicity, efficacy and tolerability of simoctocog alfa (Nuwiq ® ) in 108 previously untreated patients with severe haemophilia A planned to be treated for ≥100 exposure days or up to 5 years. The NuProtect‐Extension study collected long‐term prophylaxis data in children with severe haemophilia A.

Methods

Patients who completed the NuProtect study according to the protocol were eligible for the NuProtect‐Extension study, a prospective, multinational, non‐controlled, Phase 3b study.

Results

Of 48 patients who entered the extension study, 47 (median age 2.8 years) received prophylaxis with simoctocog alfa for a median of 24 months, with 82%–88% on a twice‐weekly or less regimen. No patient developed FVIII inhibitors during the extension study. The median (IQR) annualized bleeding rate (ABR) during prophylaxis was 0 (0–0.5) for spontaneous bleeding episodes (BEs) and 1.00 (0–1.95) for all BEs. ABRs estimated using a negative binomial model were .28 (95% CI: .15, .53) for spontaneous and 1.62 (95% CI: 1.09, 2.42) for all BEs. During the median follow‐up of 24 months, 34 (72%) patients had zero spontaneous BEs and 46 (98%) had zero spontaneous joint BEs. Efficacy in treating BEs was excellent or good for 78.2% of rated BEs, and efficacy of surgical prophylaxis was excellent for two rated surgeries. No treatment‐related adverse events were reported.

Conclusion

No FVIII inhibitors developed during long‐term prophylaxis in the NuProtect‐Extension study. Prophylaxis with simoctocog alfa was efficacious and well‐tolerated, and is therefore an attractive long‐term option for children with severe haemophilia A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AChild, PreschoolHumansFactor VIIIHemorrhageProspective StudiesTreatment OutcomeChildGlycoproteins

Stichwörter der Autor:innen

factor VIIIhaemophilia Aimmunogenicitypaediatricprophylaxissimoctocog alfa

Substanzen

Factor VIIIsimoctocog alfa (Nuwiq)Glycoproteins

Autor:innen und Institutionen

  • Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, NIHR GOSH BRC, London, UK.
  • JSC Institute of Haematology and Transfusiology, Tbilisi, Georgia.
  • Department of Hematology, Christian Medical College, Vellore, India.
  • Department of Pediatrics, Division of Hematology/Oncology/BMT, University of British Columbia and British Columbia Children's Hospital, Vancouver, Canada.
  • Department of Paediatrics, Division of Haematology/Oncology and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, Canada.
  • Department of Pediatric Hematology Oncology, Children Hospital La Timone, APHM and Inserm, UMR 1062, Aix Marseille University, Marseille, France.

ORCID-Profile: Manuel Carcao

Förderung

  • Octapharma AG

Zitieren

APA

Mathias, M., Abashidze, M., Abraham, A., Belletrutti, M. J., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J., Lambert, T., Kavardakova, N., Lohade, S., Turea, V., Wu, J. K. M., & Klukowska, A. (2023). Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients. Haemophilia. https://doi.org/10.1111/hae.14796

Vancouver

Mathias M, Abashidze M, Abraham A, Belletrutti MJ, Carcao M, Chambost H, et al. Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients. Haemophilia. 2023. doi:10.1111/hae.14796

BibTeX
@article{Mathias2023,
  author = {Mathias, Mary and Abashidze, Marina and Abraham, Aby and Belletrutti, Mark J and Carcao, Manuel and Chambost, Hervé and Chan, Anthony K C and Dubey, Leonid and Ducore, Jonathan and Lambert, Thierry and Kavardakova, Natalya and Lohade, Sunil and Turea, Valentin and Wu, John K M and Klukowska, Anna},
  title = {Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14796}
}
Kostenlos starten →